Updated: Seagen's ADC patent denied by US patent office in battle with Daiichi Sankyo
Seagen’s patent for a certain ADC technology has been made void by the US Patent and Trademark Office, marking the latest twist in a long-running dispute with Daiichi Sankyo that has largely worked in Seagen’s favor to date.
The disagreement concerns Seagen’s patent 10,808,039 which protects ADCs that comprise auristatin peptides linked with antibodies via a certain linker technology that Seagen developed during a partnership with Daiichi Sankyo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.